Prostatic Neoplasm Clinical Trial
Official title:
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide
in patients with hormone-refractory prostate cancer.
An important aspect of this study is to characterize the pharmacokinetics of thalidomide, as
well as make correlations between the degree of angiogenesis occurring in a patient and the
activity of thalidomide.
Status | Completed |
Enrollment | 64 |
Est. completion date | July 2001 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility |
DISEASE CHARACTERISTICS: Histologically documented adenocarcinoma of the prostate. Confirmation by the Clinical Center Pathology Department required. CT-defined soft tissue disease required for staging if prostate-specific antigen (PSA) less than 20 ng/mL. Progressive hormone-refractory disease for 1 month prior to entry (and after withdrawal of any antiandrogens), documented by at least one of the following: 3 consecutive rising levels of PSA at least 1 week apart. 1 measurement at least 50% greater than PSA nadir after last therapy. New bone metastasis on Tc-99 bone scintigraphy. Progression of measurable or evaluable soft-tissue metastases. Development of new area of disease. 25% increase in previously measured lesions. Total androgen ablation required. Testosterone in castrate range. Concurrent luteinizing hormone-releasing hormone (LHRH) agonist required if not surgically castrated. No prior prostate irradiation or radical prostatectomy unless other biopsiable lesions available. Urgent local problems corrected prior to entry (e.g., severe bone pain, spinal cord compression, urinary flow obstruction). No brain metastases. PRIOR/CONCURRENT THERAPY: Thyroid replaced concurrent to start of study for patients with chemical hypothyroidism. Thyroid replaced prior to study for patients with clinical hypothyroidism. Biologic Therapy: At least 4 weeks since Biologic Therapy and recovered from all toxic effects. Chemotherapy: No prior suramin. At least 4 weeks since chemotherapy and recovered from all toxic effects. Endocrine Therapy: See Disease Characteristics. At least 4 weeks since hormonal therapy except LHRH agonist therapy. Radiotherapy: See Disease Characteristics. At least 4 weeks since radiotherapy (6 weeks since strontium). Surgery: See Disease Characteristics. PATIENT CHARACTERISTICS: Age: 18 and over. Performance status: ECOG 0-2. Life expectancy: More than 3 months. Hematopoietic: Absolute granulocyte count greater than 1,000/mm(3). Platelet count greater than 75,000/mm(3). Hemoglobin greater than 8.0 g/dL (transfusion allowed if requirement maintained for more than 30 days OR bleeding identified and treated). Hepatic: Bilirubin no greater than 1.5 times normal. AST and ALT less than 2.5 times normal. Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 40 mL/min. Proteinuria no greater than 2+ OR less than 500 mg/24 hr (except patients with ureteral stents). BUN normal. Electrolytes normal. Urinalysis normal. Cardiovascular: No unstable or newly diagnosed angina. No myocardial infarction within 6 months. No NYHA class II-IV congestive heart failure. Pulmonary: No chronic obstructive lung disease requiring oxygen therapy. Neurologic: No clinically detectable peripheral neuropathy greater than grade 1. No seizures within 10 years. No anticonvulsants. No requirement for sedatives or hypnotics. OTHER: Normal thyroid function tests at least 4 weeks prior to study and throughout study. No concurrent anticoagulants. No active infection. Off antibiotics at least 1 week. Ureteral stent or Foley catheter allowed with no antibiotics. HIV negative. No concurrent life-threatening illness. No concurrent malignancies. Ability to travel to the National Institutes of Health. Adequate contraception required of sexually active patients and their partners during and for 2 months after therapy. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Bakay B, Nyhan WL. Binding of thalidomide by macromolecules in the fetal and maternal rat. J Pharmacol Exp Ther. 1968 Jun;161(2):348-60. — View Citation
Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol. 1982 Sep;7(3):317-23. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03982095 -
Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
|
||
Recruiting |
NCT05667636 -
Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
|
Phase 2 | |
Terminated |
NCT01996696 -
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
|
Phase 2 | |
Completed |
NCT01431391 -
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT03289130 -
Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
|
||
Recruiting |
NCT04462926 -
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
|
N/A | |
Completed |
NCT02729103 -
Treatment Patterns in Metastatic Prostate Cancer
|
N/A | |
Completed |
NCT00956228 -
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00247312 -
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
|
Phase 3 | |
Completed |
NCT00126854 -
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
|
N/A | |
Completed |
NCT00174863 -
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
|
Phase 2 | |
Terminated |
NCT04221828 -
Trial of NanoPac Focal Therapy for Prostate Cancer
|
Phase 2 | |
Completed |
NCT00001266 -
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03935282 -
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
|
N/A | |
Completed |
NCT03693742 -
MSG Use With 18F-DCFPyL PET/CT Imaging
|
N/A | |
Recruiting |
NCT06236789 -
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
|
||
Completed |
NCT02977143 -
Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery
|
N/A | |
Completed |
NCT02966535 -
The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial
|
N/A | |
Completed |
NCT00252460 -
CT/MRI Co-registration Prostate Cancer
|
Phase 1 | |
Completed |
NCT04398173 -
Detection Rate of Prostate Cancer in Men Undergoing MRI
|